Effect of pathohistologic complete remission (pCR) rate on the prediction of long-term prognosis following chemoradiotherapy (XRT) with cetuximab (Cet), capecitabine (CAP), and oxaliplatin (OX; Cet-CAPOX) in patients (pts) with locally advanced rectal cancer (LARC).

被引：0
|
作者：
Liersch, T.
Weiss, C.
Dellas, K.
Hipp, M.
Sauer, R.
Roedel, C.
Arnold, D.
机构：
[1] Univ Gottingen, Univ Med Ctr, Dept Gen & Visceral Surg, D-37073 Gottingen, Germany
[2] Goethe Univ Frankfurt, Dept Radiat Therapy & Oncol, D-60054 Frankfurt, Germany
[3] North European Radiooncol Ctr Kiel, Kiel, Germany
[4] Univ Regensburg, D-93053 Regensburg, Germany
[5] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany
[6] Goethe Univ Frankfurt, Dept Radiotherapy & Oncol, D-60054 Frankfurt, Germany
[7] Univ Canc Ctr Hamburg, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14035
引用
收藏
页数：1
相关论文
共 2 条
  • [1] Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC).
    Marrodan, Ines
    Rubio, Itziar
    Buque, Aitziber
    Sancho, Aintzane
    Fuente, Natalia
    Carrera, Sergio
    Arruti, Mikel
    Manel Mane, Joan
    Isabel Gutierrez, Eddy
    Iruarrizaga, Eluska
    Azkona, Eider
    Lopez-Vivanco, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
    Leichman, Cynthia G.
    McDonough, Shannon L.
    Smalley, Stephen R.
    Billingsley, Kevin G.
    Lenz, Heinz-Josef
    Beldner, Matthew A.
    Hezel, Aram F.
    Velasco, Mario R.
    Guthrie, Katherine A.
    Blanke, Charles David
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
1